Pfizer Executive Cecile Guegan Files Initial Statement of Ownership

Cecile Guegan, Executive Vice President of Pfizer Inc., has filed a Form 3, marking her initial statement of beneficial ownership. This filing is required for new insiders and establishes their starting equity position in the company as of August 17, 2026.

Key Holdings Reported:

• Common Stock: Guegan directly owns 149,505 shares of Pfizer's Common Stock.
• Derivative Securities: The filing also discloses numerous holdings of Stock Appreciation Rights (SARs) with various exercise prices and expiration dates. These rights, subject to vesting, will settle in shares of Pfizer common stock on either the fifth or seventh anniversary of their grant dates, aligning long-term incentives with company performance.

As a Form 3 is a declaration of initial holdings rather than a transactional report, its immediate market significance is low. However, it provides a crucial baseline for monitoring Guegan's future trading activity. Any subsequent purchases or sales will be reported on a Form 4, offering insights into her perspective on the company's valuation and prospects.